Cellular therapy for the infarcted myocardium

Translational Cardiology: Molecular Basis of Cardiac Metabolism, Cardiac Remodeling, Translational Therapies and Imaging Techniques

Volumn , Issue , 2012, Pages 341-390

  Den Hartogh, S C ^a   Sluijter, J P ^b   Doevendans, P A ^b   Van Laake, L W ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR THERAPY;

EID: 85025106055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-891-7_11     Document Type: Chapter

References (324)

1. Kikuchi K, Holdway JE, Werdich AA, et al. Primary contribution to zebra fi sh heart regeneration by gata4+ cardiomyocytes. Nature. 2010;464:601-5.
2. Lepilina A, Coon AN, Kikuchi K, et al. A dynamic epicardial injury response supports progenitor cell activity during zebra fi sh heart regeneration. Cell. 2006;127:607-19.
3. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebra fi sh. Science. 2002;298:2188-90.
4. Zhou B, Ma Q, Rajagopal S, et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature. 2008;454:109-13.
5. Porrello ER, Mahmoud AI, Simpson E, et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331:1078-80.
6. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344:1750-7.
7. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98-102.
8. Hsieh PCH, Segers VFM, Davis ME, et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med. 2007;13:970-4.
9. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182-9.
10. Passier R, Van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008;453:322-9.
11. Schoenhard J, Hatzopoulos A. Stem cell therapy: pieces of the puzzle. J Cardiovasc Transl Res. 2010;3:49-60.
12. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature. 2006;441:1097-9.
13. Gepstein L. Derivation and potential applications of human embryonic stem cells. Circ Res. 2002;91:866-76.
14. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46:250-6.
15. Laflamme MA, Zbinden S, Epstein SE, Murry CE. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol Mech Dis. 2007;2:307-39.
16. Fukushima S, Varela-Carver A, Coppen SR, et al. Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation. 2007;115:2254-61.
17. Menasche P, Alfieri O, Janssens S, et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: fi rst randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117:1189-200.
18. Perin EC, Dohmann HFR, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-302.
19. Segers VFM, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937-42.
20. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430-6.
21. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-8.
22. Alvarez R, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003;425:968-73.
23. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modi fi ed with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195-201.
24. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015-24.
25. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-76.
26. Laugwitz KL, Moretti A, Lam J, et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature. 2005;433:647-53.
27. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA. 1981;78:7634-8.
28. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: Homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003;100:12313-8.
29. Anversa P, Leri A, Rota M, et al. Concise review: stem cells, myocardial regeneration, and methodological artifacts. Stem Cells. 2007;25:589-601.
30. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science. 2008;322:1494-7.
31. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.
32. Menasché P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol. 2008;45:545-53.
33. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929-33.
34. Jackson KA, Majka SM, Wang H, et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001;107:1395-402.
35. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-8.
36. Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol. 2000;227:271-8.
37. Messina E, De Angelis L, Frati G, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95:911-21.
38. Ghostine S, Carrion C, Souza LCG, et al. Long-term ef fi cacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation. 2002;106:I131-6.
39. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2001;103:1920-7.
40. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98:2512-23.
41. Pouzet B, Vilquin JT, Hagège AA, et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg. 2001;71:844-51.
42. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol. 2002;34:241-9.
43. Léobon B, Garcin I, et al. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci USA. 2003;100:7808-11.
44. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. J Cell Biol. 2000;149:731-40.
45. Fernandes S, Amirault JC, Lande G, et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc Res. 2006;69:348-58.
46. Roell W, Lewalter T, Sasse P, et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature. 2007;450:819-24.
47. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005;23:845-56.
48. Lyon A, Harding S. The potential of cardiac stem cell therapy for heart failure. Curr Opin Pharmacol. 2007;7:164-70.
49. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41:1078-83.
50. Menasché P, Hagoge AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279-80.
51. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112:1748-55.
52. Gavira JJ, Herreros JS, Perez A, et al. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J Thorac Cardiovasc Surg. 2006;131: 799-804.
53. Hagege AA, Marolleau JP, Vilquin JT, et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the fi rst phase I cohort of patients. Circulation. 2006;114:I-108.
54. Siminiak T, Kalawski R, Fiszer D, et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow- up. Am Heart J. 2004;148:531-7.
55. Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol. 2003;42:2063-9.
56. Eisen HJ. Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy. Nat Clin Pract Cardiovasc Med. 2008;5:520-1.
57. Deb A, Wang S, Skelding KA, et al. Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation. 2003;107:1247-9.
58. Glaser R, Lu MM, Narula N, Epstein JA. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation. 2002;106:17-9.
59. Hocht-Zeisberg E, Kahnert H, Guan K, et al. Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. Eur Heart J. 2004;25:749-58.
60. Muller P, Pfeiffer P, Koglin J, et al. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation. 2002;106:31-5.
61. Quaini F, Urbanek K, Beltrami AP, et al. Chimerism of the transplanted heart. N Engl J Med. 2002;346:5-15.
62. Laflamme MA, Myerson D, Saffitz JE, Murry CE. Evidence for cardiomyocyte repopulation by extracardiac progenitors in transplanted human hearts. Circ Res. 2002;90:634-40.
63. Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest. 2005;115:326-38.
64. Bertoncello I, Williams B. Hematopoietic Stem Cell Characterization by Hoechst 33342 and Rhodamine 123 staining. Flow Cytometry Protocols. 2004:181-200 65.
65. Wolf NS, Koné A, Priestley GV, Bartelmez SH. In vivo and in vitro characterization of longterm repopulating primitive hematopoietic cells isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp Hematol. 1993;21(5):614-22.
66. Fleming WH, Alpern EJ, Uchida N, et al. Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells. J Cell Biol. 1993;122:897-902.
67. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369-77.
68. Goodell MA, Rosenzweig M, Kim H, et al. Dye ef fl ux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337-45.
69. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5.
70. Kajstura J, Rota M, Whang B, et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res. 2005;96:127-37.
71. Rota M, Kajstura J, Hosoda T, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci. 2007;104:17783-8.
72. Balsam LB, Wagers AJ, Christensen JL, et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428:668-73.
73. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664-8.
74. Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004;10:494-501.
75. Scherschel JA, Soonpaa MH, Srour EF, Field LJ, Rubart M. Adult bone marrow-derived cells do not acquire functional attributes of cardiomyocytes when transplanted into peri-infarct myocardium. Mol Ther. 2008;16:1129-37.
76. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85:221-8.
77. Loges S, Fehse B, Brockmann MA, et al. Identi fi cation of the adult human hemangioblast. Stem Cells Dev. 2004;13:229-42.
78. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702-12.
79. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 2002;109:337-46.
80. Pujol BF, Lucibello FC, Gehling UM, et al. Endothelial-like cells derived from human CD14 positive monocytes. Differentiation. 2000;65:287-300.
81. Ingram DA, Mead LE, Moore DB, et al. Vessel wall-ûderived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood. 2005;105:2783-6.
82. Dzau VJ, Gnecchi M, Pachori AS. Enhancing stem cell therapy through genetic modi fi cation. J Am Coll Cardiol. 2005;46:1351-3.
83. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu Rev Med. 2004;56:79-101.
84. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003;108:2710-5.
85. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-6.
86. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
87. Young PP, Vaughan DE, Hatzopoulos AK. Biologic properties of endothelial progenitor cells and their potential for cell therapy [abstract]. Prog Cardiovasc Dis. 2007;49:421-9.
88. Aicher A, Zeiher AM, Dimmeler S. Mobilizing endothelial progenitor cells. Hypertension. 2005;45:321-5.
89. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-72.
90. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:697-703.
91. Bengel F, Schachinger V, Dimmeler S. Cell-based therapies and imaging in cardiology. Eur J Nucl Med Mol Imaging. 2005;32:S404-16.
92. Dobaczewski M, Bujak M, Zymek P, et al. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 2006;324:475-88.
93. Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935-47.
94. Young PP, Hofling AA, Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc Natl Acad Sci USA. 2002;99:11951-6.
95. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110:1933-9.
96. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase- dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108:3115-21.
97. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation. 2003;107:3059-65.
98. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164-9.
99. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res. 2004;94:230-8.
100. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation. 2004;110:962-8.
101. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83:59-115.
102. Cleaver O, Melton DA. Endothelial signaling during development. Nat Med. 2003;9:661-8.
103. Sprengers RW, Moll FL, Teraa M, Verhaar MC. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg. 2010;51:1564-8.
104. Westerweel PE, Visseren FLJ, Hajer GR, et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ ezetimibe combination therapy. Eur Heart J. 2008;29:2808-17.
105. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for de fi ning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
106. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med. 2001;7:259-64.
107. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res. 2007;100:1249-60.
108. Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200:123-35.
109. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7.
110. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705.
111. Fukuda K. Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue-engineering. Artif Organs. 2001;25:187-93.
112. Hakuno D, Fukuda K, Makino S, et al. Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation. 2002;105:380-6.
113. Rangappa S, Entwistle JW, Wechsler AS, Kresh JY. Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. J Thorac Cardiovasc Surg. 2003;126:124-32.
114. Xu M, Wani M, Dai YS, et al. Differentiation of bone marrow stromal cells into the cardiac phenotype requires intercellular communication with myocytes. Circulation. 2004;110:2658-65.
115. Shake JG, Gruber PJ, Baumgartner WA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg. 2002;73:1919-26.
116. Min JY, Sullivan MF, Yang Y, et al. Signi fi cant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs. Ann Thorac Surg. 2002;74:1568-75.
117. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 2005;102:11474-9.
118. Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110:1362-9.
119. Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006;14:840-50.
120. Silva J, Chambers I, Pollard S, Smith A. Nanog promotes transfer of pluripotency after cell fusion. Nature. 2006;441:997-1001.
121. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modi fi ed mesenchymal stem cells. Nat Med. 2005;11:367-8.
122. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Aktmodi fi ed mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20:661-9.
123. Tang YL, Zhao Q, Zhang YC, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2004;117:3-10.
124. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2004;104:3581-7.
125. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol. 1996;166(3):585-92.
126. Barry FP, Murphy JM, English K, Mahon BP. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 2005;14:252-65.
127. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076-84.
128. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspeci fi c mitogenic stimuli. Blood. 2002;99:3838-43.
129. Griffin MD, Ritter T, Mahon BP. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther. 2010;21:1641-55.
130. Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2005;25:1168-73.
131. Tang YL, Tang Y, Zhang YC, et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46:1339-50.
132. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167:989-97.
133. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scienti fi c foundations of cardiac repair. J Clin Invest. 2005;115:572-83.
134. Erbs S, Linke A, Schachinger V, et al. Restoration of microvascular function in the infarctrelated artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the doppler substudy of the reinfusion of enriched progenitor cells and infarct remodeling in acute myocardial infarction (REPAIR-AMI) trial. Circulation. 2007;116:366-74.
135. Bocchi EA, Esteves-Filho A, Bellotti G, et al. Left ventricular regional wall motion, ejection fraction, and geometry after partial left ventriculectomy. In fl uence of associated mitral valve repair. Eur J Cardiothorac Surg. 2000;18:458-65.
136. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-8.
137. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) Trial. Circulation. 2006;113:1287-94.
138. Rosenzweig A. Cardiac cell therapy-mixed results from mixed cells. N Engl J Med. 2006;355:1274-7.
139. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:3009-17.
140. Schachinger V, Assmus B, Honold J, et al. Normalization of coronary blood fl ow in the infarct-related artery after intracoronary progenitor cell therapy. Clin Res Cardiol. 2006;95:13-22.
141. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-21.
142. Schachinger V, Assmus B, Erbs S, et al. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial. Eur J Heart Fail. 2009;11:973-9.
143. Schachinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: fi nal 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775-83.
144. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113-21.
145. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355:1199-209.
146. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133- positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005;112:178.
147. Choi JH, Choi J, Lee WS, et al. Lack of additional bene fi t of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction. Circ J. 2007;71:486-94.
148. Tatsumi T, Ashihara E, Yasui T, et al. Intracoronary transplantation of non-expanded peripheral blood-derived mononuclear cells promotes improvement of cardiac function in patients with acute myocardial infarction. Circ J. 2007;71:1199-207.
149. Li Ming Z, Yuan-zhe J, Wei-wei Z, et al. The clinical study of autologous peripheral blood stem cell transplantation by intracoronory infusion in patients with acute myocardial infarction (AMI) [abstract]. Int J Cardiol. 2007;115:52-6.
150. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111:2198-202.
151. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol. 1996;28:1737-46.
152. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 1998;83:15-26.
153. Anversa P, Kajstura J. Ventricular myocytes are not terminally differentiated in the adult mammalian heart. Circ Res. 1998;83:1-14.
154. Kajstura J, Gurusamy N, Ogorek B, et al. Myocyte turnover in the aging human heart. Circ Res. 2010;107:1374-86.
155. Martin CM, Meeson AP, Robertson SM, et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identi fi es cardiac SP cells in the developing and adult heart. Dev Biol. 2004;265:262-75.
156. Andersen DC, Andersen P, Schneider M, Jensen HB, Sheikh SP. Murine "Cardiospheres" are not a source of stem cells with cardiomyogenic potential. Stem Cells. 2009;27:1571-81.
157. Moretti A, Caron L, Nakano A, et al. Multipotent embryonic Isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversi fi cation [abstract]. Cell. 2006;127:1151-65.
158. Cai CL, Liang X, Shi Y, et al. Isl1 identi fi es a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart [abstract]. Dev Cell. 2003;5:877-89.
159. Sun Y, Liang X, Najafi N, et al. Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. Dev Biol. 2007;304:286-96.
160. Martin-Puig S, Wang Z, Chien KR. Lives of a heart cell: tracing the origins of cardiac progenitors [abstract]. Cell Stem Cell. 2008;2:320-31.
161. Goumans MJ, de Boer TP, Smits AM, et al. TGF-beta1 induces ef fi cient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res. 2007;1(2):138-49. Epub 2008 Mar 12.
162. van Vliet P, Roccio M, Smits A, et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Netherlands Heart J. 2008;16:163-9.
163. van Vliet P, de Boer T, van der Heyden M, et al. Hyperpolarization induces differentiation in human cardiomyocyte progenitor cells. Stem Cell Rev Rep. 2010;6:178-85.
164. De Boer TP, Van Veen TAB, Jonsson MKB, et al. Human cardiomyocyte progenitor cellderived cardiomyocytes display a maturated electrical phenotype. J Mol Cell Cardiol. 2010;48:254-60.
165. van Vliet P, Smits AM, De Boer TP, et al. Foetal and adult cardiomyocyte progenitor cells have different developmental potential. J Cell Mol Med. 2010;14:861-70.
166. Smits AM, van Vliet P, Metz CH, et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc. 2009;4:232-43.
167. Hassink RJ, Pasumarthi KB, Nakajima H, et al. Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc Res. 2008;78:18-25.
168. Smart N, Rossdeutsch A, Riley P. Thymosin B4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10:229-41.
169. van Tuyn J, Atsma DE, Winter EM, et al. Epicardial cells of human adults can undergo an epithelial-to-mesenchymal transition and obtain characteristics of smooth muscle cells in vitro. Stem Cells. 2007;25:271-8.
170. Wada AM, Smith TK, Osler ME, Reese DE, Bader DM. Epicardial/Mesothelial cell line retains vasculogenic potential of embryonic epicardium. Circ Res. 2003;92:525-31.
171. Lie-Venema H, van den Akker NM, Bax NA, et al. Origin, fate, and function of epicardiumderived cells (EPDCs) in normal and abnormal cardiac development. Sci World J. 2007;7:1777-98.
172. Winter EM, Grauss RW, Hogers B, et al. Preservation of left ventricular function and attenuation of remodeling after transplantation of human epicardium-derived cells into the infarcted mouse heart. Circulation. 2007;116:917-27.
173. Morabito CJ, Dettman RW, Kattan J, Collier JM, Bristow J. Positive and negative regulation of epicardial-mesenchymal transformation during avian heart development. Dev Biol. 2001;234:204-15.
174. Jopling C, Sleep E, Raya M, et al. Zebra fi sh heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature. 2010;464:606-9.
175. Limana F, Zacheo A, Mocini D, et al. Identi fi cation of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res. 2007;101:1255-65.
176. Limana F, Bertolami C, Mangoni A, et al. Myocardial infarction induces embryonic reprogramming of epicardial c-kit+ cells: role of the pericardial fl uid. J Mol Cell Cardiol. 2010;48:609-18.
177. van Wijk B, van den Hoff M. Epicardium and myocardium originate from a common cardiogenic precursor pool. Trends Cardiovasc Med. 2010;20:1-7.
178. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-6.
179. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145-7.
180. Chambers I, Silva J, Colby D, et al. Nanog safeguards pluripotency and mediates germline development. Nature. 2007;450:1230-4.
181. Silva J, Barrandon O, Nichols J, et al. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008;6:e253.
182. Pease S, Williams RL. Formation of germ-line chimeras from embryonic stem cells maintained with recombinant leukemia inhibitory factor. Exp Cell Res. 1990;190(2):209-11.
183. Williams RL, Hilton DJ, Pease S, et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature. 1988;336:684-7.
184. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3 [abstract]. Cell. 2003;115:281-92.
185. Kunath T, Saba-El-Leil MK, Almousailleakh M, et al. FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development. 2007;134:2895-902.
186. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci. 2005;118:4495-509.
187. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108:407-14.
188. Mummery C, Ward-van Oostwaard D, Doevendans P, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003;107:2733-40.
189. Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002;91:501-8.
190. Huber I, Itzhaki I, Caspi O, et al. Identi fi cation and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J. 2007;21:2551-63.
191. Laflamme MA, Gold J, Xu C, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005;167:663-71.
192. Brand T. Heart development: molecular insights into cardiac speci fi cation and early morphogenesis. Dev Biol. 2003;258:1-19.
193. Mummery C, Heyden MAG, Boer TP et al. Cardiomyocytes From Human and Mouse Embryonic Stem Cells. In: Hauser H, Fussenegger M, eds. Tissue Engineering.: Humana Press; 2007:249-272
194. 194. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development [abstract]. Cell. 2008;132:661-80.
195. Mummery CL, van Achterberg TAE, van den Eijnden-van Raaij AJ, et al. Visceral-endodermlike cell lines induce differentiation of murine P19 embryonal carcinoma cells. Differentiation. 1991;46:51-60.
196. Graichen R, Xu X, Braam SR, et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation. 2008;76:357-70.
197. Yao S, Chen S, Clark J, et al. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically de fi ned conditions. Proc Natl Acad Sci. 2006;103:6907-12.
198. Paige SL, Osugi T, Afanasiev OK, et al. Endogenous Wnt/B-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One. 2010;5:e11134.
199. Srivastava D. Making or breaking the heart: from lineage determination to morphogenesis. Cell. 2006;126:1037-48.
200. Beqqali A, Kloots J, Ward-van Oostwaard D, Mummery C, Passier R. Genome-wide transcriptional pro fi ling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells. 2006;24:1956-67.
201. Cai J, Yi FF, Yang XC, et al. Transplantation of embryonic stem cell-derived cardiomyocytes improves cardiac function in infarcted rat hearts. Cytotherapy. 2007;9:283-91.
202. Passier R, Mummery C. Cardiomyocyte differentiation from embryonic and adult stem cells. Curr Opin Biotechnol. 2005;16:498-502.
203. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003;93:32-9.
204. Caspi O, Huber I, Kehat I, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol. 2007;50:1884-93.
205. Nussbaum J, Minami E, Laflamme MA, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007;21:1345-57.
206. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation. 2005;112:I-166.
207. Hattori F, Chen H, Yamashita H, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods. 2010;7:61-6.
208. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fi broblasts by de fi ned factors. Cell. 2007;131:861-72.
209. Xu C, Police S, Hassanipour M, Gold JD. Cardiac bodies: a novel culture method for enrichment of cardiomyocytes derived from human embryonic stem cells. Stem Cells Dev. 2006;15:631-9.
210. Mummery C. Sorting cardiomyocytes: a simple solution after all? Nat Methods. 2010;7:40-2.
211. Anderson D, Self T, Mellor IR, et al. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther. 2007;15:2027-36.
212. Van Laake LW, Qian L, Cheng P, et al. Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circ Res. 2010;107:340-7.
213. Kattman SJ, Huber TL, Keller G. Multipotent Flk-1+ cardiovascular progenitor cellságive rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages [abstract]. Dev Cell. 2006;11:723-32.
214. Christoforou N, Miller RA, Hill CM, et al. Mouse ES cell-derived cardiac precursor cells are multipotent and facilitate identi fi cation of novel cardiac genes. J Clin Invest. 2008;118:894-903.
215. Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453:524-8.
216. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996;98:216-24.
217. Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004;22:1282-9.
218. Xue T, Cho HC, Akar FG, et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation. 2005;111:11-20.
219. Van Laake LW, Passier R, Monshouwer-Kloots J, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007;1:9-24.
220. Dai W, Field LJ, Rubart M, et al. Survival and maturation of human embryonic stem cellderived cardiomyocytes in rat hearts. J Mol Cell Cardiol. 2007;43:504-16.
221. Van Laake L, van Donselaar E, Monshouwer-Kloots J, et al. Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. Cell Mol Life Sci. 2010;67:277-90.
222. Min JY, Yang Y, Sullivan MF, et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg. 2003;125:361-9.
223. Frangogiannis NG, Smith CW, Entman ML. The in fl ammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
224. Nian M, Lee P, Khaper N, Liu P. In fl ammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-53.
225. Van Laake LW, Passier R, Doevendans PA, Mummery CL. Human embryonic stem cellderived cardiomyocytes and cardiac repair in rodents. Circ Res. 2008;102:1008-10.
226. Van Laake LW, Passier R, den Ouden K, et al. Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Res. 2009;3:106-12.
227. Christoforou N, Oskouei BN, Esteso P, et al. Implantation of mouse embryonic stem cellderived cardiac progenitor cells preserves function of infarcted murine hearts. PLoS One. 2010;5:e11536.
228. Lev SOPH, Kehat IZHA, Gepstein LIOR. Differentiation pathways in human embryonic stem cell-derived cardiomyocytes. Ann N Y Acad Sci. 2005;1047:50-65.
229. 2+ transients in Langendorff-perfused mouse hearts. Am J Physiol Cell Physiol. 2003;284:C1654-68.
230. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
231. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fi broblast cultures by de fi ned factors. Cell. 2006;126:663-76.
232. Byrne JA, Pedersen DA, Clepper LL, et al. Producing primate embryonic stem cells by somatic cell nuclear transfer. Nature. 2007;450:497-502.
233. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science. 2005;309:1369-73.
234. Yu J, Vodyanik MA, He P, Slukvin II, Thomson JA. Human embryonic stem cells reprogram myeloid precursors following cell-cell fusion. Stem Cells. 2006;24:168-76.
235. Maherali N, Sridharan R, Xie W, et al. Directly reprogrammed fi broblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007;1:55-70.
236. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313-7.
237. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fi broblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318-24.
238. Marion RM, Strati K, Li H, et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells [abstract]. Cell Stem Cell. 2009;4:141-54.
239. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fi broblasts. Proc Natl Acad Sci. 2008;105:2883-8.
240. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with de fi ned factors. Nature. 2008;451:141-6.
241. Verrey F, Closs E, Wagner C, et al. CATs and HATs: the SLC7 family of amino acid transporters. P fl ++=ue Archiv European. J Physiol. 2004;447:532-42.
242. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008;118:507-17.
243. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008;118:498-506.
244. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-41.
245. Zwi L, Caspi O, Arbel G, et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation. 2009;120:1513-23.
246. Gupta M, Illich D, Gaarz A, et al. Global transcriptional pro fi les of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol. 2010;10:98.
247. Nelson TJ, Martinez-Fernandez A, Yamada S, et al. Repair of acute myocardial Infarction by human stemness factors induced pluripotent stem cells. Circulation. 2009;120:408-16.
248. Freund C, Mummery CL. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem. 2009;107:592-9.
249. Yamanaka S. A fresh look at iPS cells. Cell. 2009;137:13-7.
250. Moretti A, Bellin M, Welling A, et al. Patient-speci fi c induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363:1397-409.
251. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949-53.
252. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science. 2008;322:945-9.
253. Li Y, Zhang Q, Yin X, et al. Generation of iPSCs from mouse fi broblasts with a single gene, Oct4, and small molecules. Cell Res. 2011;21:196-204.
254. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472-6.
255. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4:381-4.
256. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by de fi ned factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26:795-7.
257. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fi broblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269-75.
258. Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fi broblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008;3:568-74.
259. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med. 2009;15:59-68.
260. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev. 2010;24:2239-63.
261. Meissner A. Epigenetic modi fi cations in pluripotent and differentiated cells. Nat Biotechnol. 2010;28:1079-88.
262. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5:111-23.
263. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-speci fi c CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fi broblasts. Nat Genet. 2009;41:1350-3.
264. Feng Q, Lu SJ, Klimanskaya I, et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells. 2010;28:704-12.
265. Pick M, Stelzer Y, Bar-Nur O, et al. Clone- and gene-speci fi c aberrations of parental imprinting in human induced pluripotent stem cells. Stem Cells. 2009;27:2686-90.
266. Choi J, Costa ML, Mermelstein CS, et al. MyoD converts primary dermal fi broblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci. 1990;87:7988-92.
267. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to B-cells. Nature. 2008;455:627-32.
268. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fi broblasts to functional neurons by de fi ned factors. Nature. 2010;463:1035-41.
269. Ieda M, Fu JD, Gado-Olguin P, et al. Direct reprogramming of fi broblasts into functional cardiomyocytes by de fi ned factors. Cell. 2010;142:375-86.
270. Passier R, Mummery C. Getting to the heart of the matter: direct reprogramming to cardiomyocytes. Cell Stem Cell. 2010;7:139-41.
271. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26:1196-204.
272. Massa M, Rosti V, Ferrario M, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105:199-206.
273. Aicher A, Brenner W, Zuhayra M, et al. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation. 2003;107:2134-9.
274. Moelker AD, Baks T, Wever KMAM, et al. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J Mol Cell Cardiol. 2007;42:735-45.
275. Funcke F, Hoyer H, Brenig F, et al. Characterisation of the interaction between circulating and in vitro cultivated endothelial progenitor cells and the endothelial barrier. Eur J Cell Biol. 2008;87:81-90.
276. Schmidt A, Ladage D, Steingen C, et al. Mesenchymal stem cells transmigrate over the endothelial barrier. Eur J Cell Biol. 2006;85:1179-88.
277. Schuleri KH, Boyle AJ, Hare JM. Mesenchymal stem cells for cardiac regenerative therapy. In: Kauser K, Zeiher AM, editors. Bone marrow-derived progenitors. Berlin, Heidelberg: Springer; 2007. p. 195-218.
278. Suzuki K, Murtuza B, Beauchamp JR, et al. Role of interleukin-1(beta) in acute in flammation and graft death after cell transplantation to the heart. Circulation. 2004;110:II-219.
279. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: in fl uence on cardiac form and function. Physiol Rev. 2007;87:1285-342.
280. Gaudesius G, Miragoli M, Thomas SP, Rohr S. Coupling of cardiac electrical activity over extended distances by fi broblasts of cardiac origin. Circ Res. 2003;93:421-8.
281. Parker KK, Tan J, Chen CS, Tung L. Myo fi brillar architecture in engineered cardiac myocytes. Circ Res. 2008;103:340-2.
282. Radisic M, Euloth M, Yang L, et al. High-density seeding of myocyte cells for cardiac tissue engineering. Biotechnol Bioeng. 2003;82:403-14.
283. Radisic M, Marsano A, Maidhof R, Wang Y, Vunjak-Novakovic G. Cardiac tissue engineering using perfusion bioreactor systems. Nat Protoc. 2008;3:719-38.
284. Zimmermann WH, Melnychenko I, Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials. 2004;25:1639-47.
285. Zimmermann WH. Remuscularizing failing hearts with tissue engineered myocardium. Antioxid Redox Signal. 2009;11:2011-23.
286. Shimizu T, Yamato M, Isoi Y, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res. 2002;90:e40-8.
287. Sekine H, Shimizu T, Yang J, Kobayashi E, Okano T. Pulsatile myocardial tubes fabricated with cell sheet engineering. Circulation. 2006;114:I-87.
288. Zimmermann WH, Melnychenko I, Wasmeier G, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. 2006;12:452-8.
289. Zakharova L, Mastroeni D, Mutlu N, et al. Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res. 2010;87:40-9.
290. Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol. 2008;45:567-81.
291. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-27.
292. Zhang M, Methot D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33:907-21.
293. Lim SY, Kim YS, Ahn Y, et al. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res. 2006;70:530-42.
294. Kutschka I, Kofidis T, Chen IY, et al. Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation. 2006;114:174.
295. Mosser DD, Caron AW, Bourget L, Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol. 1997;17:5317-27.
296. Maurel A, Azarnoush K, Sabbah L, et al. Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Transplantation. 2005;80(5):660-5.
297. Pasumarthi KBS, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res. 2005;96:110-8.
298. Woo YJ, Panlilio CM, Cheng RK, et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation. 2006;114:206.
299. Engel FB, Hsieh PCH, Lee RT, Keating MT. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci. 2006;103:15546-51.
300. Bersell K, Arab S, Haring B, Kühn B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury [abstract]. Cell. 2009;138:257-70.
301. Davis ME, Hsieh PCH, Takahashi T, et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nano fi bers improves cell therapy for myocardial infarction. Proc Natl Acad Sci. 2006;103:8155-60.
302. Liu TB, Fedak PWM, Weisel RD, et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol. 2004;287:H2840-9.
303. Tang YL, Zhao Q, Qin X, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80:229-37.
304. Takano H, Ueda K, Hasegawa H, Komuro I. G-CSF therapy for acute myocardial infarction. Trends Pharmacol Sci. 2007;28:512-7.
305. Litvin J, Zhu S, Norris R, Markwald R. Periostin family of proteins: therapeutic targets for heart disease. Anat Rec. 2005;287A:1205-12.
306. Kuhn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med. 2007;13:962-9.
307. Levkau B, Schafers M, Wohlschlaeger J, et al. Survivin determines cardiac function by controlling total cardiomyocyte number. Circulation. 2008;117:1583-93.
308. Bonacchi M, Nistri S, Nanni C, et al. Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy. J Cell Mol Med. 2009;13:3437-48.
309. Du XJ, Xu Q, Lekgabe E, et al. Reversal of cardiac fi brosis and related dysfunction by relaxin. Ann N Y Acad Sci. 2009;1160:278-84.
310. Formigli L, Francini F, Nistri S, et al. Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J Mol Cell Cardiol. 2009;47:335-45.
311. Bock-Marquette I, Saxena A, White MD, MichaelDiMaio J, Srivastava D. Thymosin [beta]4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466-72.
312. Singla DK, Lyons GE, Kamp TJ. Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:H1308-14.
313. Singla DK, McDonald DE. Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. Am J Physiol Heart Circ Physiol. 2007;293:H1590-5.
314. Singla DK. Embryonic stem cells in cardiac repair and regeneration. Antioxid Redox Signal. 2009;11:1857-63.
315. Akao M, Ohler A, O'Rourke B, Marban E. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res. 2001;88:1267-75.
316. Levenberg S, Ferreira LS, Chen-Konak L, Kraehenbuehl TP, Langer R. Isolation, differentiation and characterization of vascular cells derived from human embryonic stem cells. Nat Protoc. 2010;5:1115-26.
317. Wu SM, Fujiwara Y, Cibulsky SM, et al. Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart [abstract]. Cell. 2006;127:1137-50.
318. Reinecke H, Zhang M, Bartosek T, Murry CE. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 1999;100:193-202.
319. Formigli L, Francini F, Tani A, et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am J Physiol Cell Physiol. 2005;288:C795-804.
320. Mayshar Y, Ben-David U, Lavon N, et al. Identi fi cation and classi fi cation of chromosomal aberrations in human induced pluripotent stem cells [abstract]. Cell Stem Cell. 2010;7:521-31.
321. Spits C, Mateizel I, Geens M, et al. Recurrent chromosomal abnormalities in human embryonic stem cells. Nat Biotechnol. 2008;26:1361-3.
322. Van Laake LW, van den Driesche S, Post S, et al. Endoglin has a crucial role in blood cellmediated vascular repair. Circulation. 2006;114:2288-97.
323. Chidgey AP, Layton D, Trounson A, Boyd RL. Tolerance strategies for stem-cell-based therapies. Nature. 2008;453:330-7.
324. Swijnenburg RJ, Schrepfer S, Govaert JA, et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci. 2008;105: 12991-6.